Myasthenia gravis associated with etanercept therapy

Muscle and Nerve

Volumn 39, Issue 6, 2009, Pages 866-870

  Fee, Dominic B ^a   Kasarskis, Edward J ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Acetylcholine receptor antibodies; Enbrel; Etanercept; Myasthenia gravis; Pathophysiology

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG SAFETY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; HUMAN; MALE; MYASTHENIA GRAVIS; NERVE CONDUCTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPEECH DISORDER; TENDON REFLEX;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DEGLUTITION DISORDERS; HUMANS; IMMUNOGLOBULIN G; MALE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; PHARYNX; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67049145696     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21280     Document Type: Article

References (47)

1. Andonopoulos AP, Terzis E, Tsibri E, Papasteriades CA, Papapetropoulos T. D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence? Clin Rheumatol 1994;13:586-588.
2. Appel SH, Anwyl R, McAdams MW, Elias S. Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci U S A 1977;74:2130-2134. (Pubitemid 8123625)
3. Appel SH, Blosser JC, McManaman JL, Ashizawa T. Acetylcholine receptor turnover in myasthenia gravis. Am J Physiol 1982;243:E31-36. (Pubitemid 12092517)
4. Bal A, Gurcay E, Aydog E, Unlu E, Umay E, Cakci A. Neuralgic amyotrophy due to rheumatoid arthritis or etanercept: causal association or coincidence? Indian J Med Res 2008;127:89-90.
5. Bender AN, Ringel SP, Engel WK, Daniels MP, Vogel Z. Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction. Lancet 1975;1:607-609.
6. Bongioanni P, Ricciardi R, Pellegrino D, Romano MR. T-cell tumor necrosis factor-alpha receptor binding in myasthenic patients. J Neuroimmunol 1999;93:203-207. (Pubitemid 29051566)
7. Christadoss P, Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol 2002;122:186-190. (Pubitemid 34075505)
8. Christensen PB, Jensen TS, Tsiropoulos I, Sorensen T, Kjaer M, Hojer-Pedersen E, et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand 1995;91:192-195.
9. Ciompi ML, Marchetti G, Bazzichi L, Puccetti L, Agelli M. D-penicillamine and gold salt treatments were complicated by myasthenia and pemphigus, respectively, in the same patient with rheumatoid arthritis. Rheumatol Int 1995;15:95-97.
10. Cuenoud S, Feltkamp TE, Fulpius BW, Oosterhuis HJ. Antibodies to acetylcholine receptor in patients with thymoma but without myasthenia gravis. Neurology 1980;30:201-202. (Pubitemid 10133444)
11. Delamere JP, Jobson S, Mackintosh LP, Wells L, Walton KW. Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features. Ann Rheum Dis 1983;42:500-504.
12. Duan RS, Wang HB, Yang JS, Scallon B, Link H, Xiao BG. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 2002;19:169-174. (Pubitemid 36262931)
13. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-361. (Pubitemid 34257750)
14. Fulpius BW, Miskin R, Reich E. Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors. Proc Natl Acad Sci U S A 1980;77:4326-4330. (Pubitemid 10022604)
15. Goluszko E, Deng C, Poussin MA, Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 2002;122:85-93. (Pubitemid 34075493)
16. Guan YZ, Cui LY, Li YF, Zhang JB. Tumor necrosis factor-alpha polymorphism and secretion in myasthenia gravis. Chin Med Sci J 2005;20:104-107. (Pubitemid 41058485)
17. Hanaoka BY, Libecco J, Rensel M, Hajj-Ali RA. Peripheral mononeuropathy with etanercept use: case report. J Rheumatol 2008;35:182.
18. Hjelmstrom P, Peacock CS, Giscombe R, Pirskanen R, Lefvert AK, Blackwell JM, et al. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis. J Neuroimmunol 1998;88:137-143. (Pubitemid 28342914)
19. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526-538. (Pubitemid 18146178)
20. Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999;94:165-171. (Pubitemid 29071257)
21. Kakoulidou M, Bjelak S, Pirskanen R, Lefvert AK. A clinical and immunological study of a myasthenia gravis patient treated with infliximab. Acta Neurol Scand 2007;115:279-283. (Pubitemid 46449590)
22. Kuks JB, Limburg PC, Horst G, Oosterhuis HJ. Antibodies to skeletal muscle in myasthenia gravis. Part 3. Relation with clinical course and therapy. J Neurol Sci 1993;120:168-173. (Pubitemid 24040595)
23. Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403. (Pubitemid 8323892)
24. Li H, Shi FD, Bai X, Huang Y, Diab A, He B, et al. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis. J Neurol Sci 1998;161:40-46. (Pubitemid 28559182)
25. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357-370.
26. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
27. Mohan S, Barohn RJ, Krolick KA. Unexpected cross-reactivity between myosin and a main immunogenic region (MIR) of the acetylcholine receptor by antisera obtained from myasthenia gravis patients. Clin Immunol Immunopathol 1992;64:218-226.
28. Morel E, Feuillet-Fieux MN, Vernet-der Garabedian B, Raimond F, D'Anglejan J, Bataille R, et al. Autoantibodies in D-penicillamine-induced myasthenia gravis: a comparison with idiopathic myasthenia and rheumatoid arthritis. Clin Immunol Immunopathol 1991;58:318-330.
29. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147. (Pubitemid 27306284)
30. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 1997;31:1335-1338.
31. Oosterhuis HJ, de Haas WH. Rheumatic diseases in patients with myasthenia gravis. An epidemiological and clinical investigation. Acta Neurol Scand 1968;44:219-227.
32. Oosterhuis HJ, Limburg PC, Hummel-Tappel E, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 1983;58:371-385. (Pubitemid 13138257)
33. Oosterhuis HJ, Limburg PC, Hummel-Tappel E, Van den Burg W, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy. J Neurol Sci 1985;69:335-343. (Pubitemid 15074627)
34. Penn AS, Low BW, Jaffe IA, Luo L, Jacques JJ. Drug-induced autoimmune myasthenia gravis. Ann N Y Acad Sci 1998;841:433-449. (Pubitemid 28362881)
35. Rey E, Zeidel M, Rhine C, Tami J, Krolick K, Fischbach M, et al. Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries. Clin Immunol 2000;96:269-279. (Pubitemid 30677776)
36. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005;64:1468-1470. (Pubitemid 40570527)
37. Rowin J, Meriggioli MN, Tuzun E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004;63:2390-2392. (Pubitemid 40024358)
38. Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol 1978;37:212-223. (Pubitemid 8318389)
39. Seybold ME, Lindstrom JM. Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis. Ann N Y Acad Sci 1981;377:292-306.
40. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006;54:1429-1434.
41. Skeie GO, Pandey JP, Aarli JA, Gilhus NE. TNFA and TNFB polymorphisms in myasthenia gravis. Arch Neurol 1999;56:457-461. (Pubitemid 29166340)
42. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001;13:164-169. (Pubitemid 32430066)
43. Tindall RS. Humoral immunity in myasthenia gravis: clinical correlations of anti-receptor antibody avidity and titer. Ann N Y Acad Sci 1981;377:316-331.
44. Tuzun E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-MG gamma benefit from etanercept treatment. J Autoimmun 2005;24:261-268. (Pubitemid 40545889)
45. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15:185-194. (Pubitemid 17075151)
46. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A 1980;77:755-759. (Pubitemid 10108379)
47. Yasuda M, Loo M, Shiokawa S, Wada T, Suenaga Y, Nobunaga M. Mixed connective tissue disease presenting myasthenia gravis. Intern Med 1993;32:633-637.